Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
about
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyCIViC databaseAdvances in sarcoma diagnostics and treatmentEpigenetic modulators as therapeutic targets in prostate cancerEZH2 as a mediator of treatment resistance in melanomaRole of EZH2 histone methyltrasferase in melanoma progression and metastasisSomatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaThin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling.Precision medicine driven by cancer systems biology.Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.Orchestration of H3K27 methylation: mechanisms and therapeutic implication.Polycomb Repressor Complex 2 in Genomic Instability and CancerRegulation of cancer epigenomes with a histone-binding synthetic transcription factor.Epigenetic actions of environmental factors and promising drugs for cancer therapy.Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance.Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
P2860
Q26783032-DBE5D7FF-50D3-44DF-8E2D-E0CC4723FD68Q27612411-091FE489-3EDA-4D19-B45E-4A2D6D730268Q28069695-0D065053-61B3-4E4D-B159-D69DEEA4F372Q28071912-CC2D6D83-204F-4920-B8FB-D9525F1FBFC5Q28074492-4A37D1E7-673C-4F20-94C1-02BD656F7E88Q37187733-10468C55-5A66-4807-9053-FF14455C0127Q37218158-B3A9048F-6662-4859-9AB8-986A4A6B713FQ37327493-FCBEB09F-DE5B-440D-BA39-9645802A1761Q37392656-C983FAEA-0592-40C5-B93E-1A90D987E360Q37520284-561591CC-D07D-4355-8DF9-EA5100A57FFBQ37742635-D00B979A-7565-4A9C-8FDF-69CF9748BDF6Q38874383-79843D3C-595E-4234-A9AE-BC5C61D31AA6Q38993869-BC2DF0C7-0420-428F-9CC9-3DD4E7CFC5BBQ39440781-B6CAE35E-43DE-4C0A-988B-DE5E1E4038FDQ41573279-21A251DD-8D9B-4C52-BF72-18B97E99C72DQ41734326-DE6CE30E-B887-41E7-A85F-4BBAC2DEE52CQ49724675-EC58A05C-04E8-47A9-A8CC-235703AA91A5Q52608481-66600453-949C-4A52-AEFF-A39B253BE511Q55379234-5202AD9A-BEA9-4F3B-89CF-8E0A86CF56F1
P2860
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Targeting activating mutations ...... sion of tumor suppressor genes
@ast
Targeting activating mutations ...... sion of tumor suppressor genes
@en
Targeting activating mutations ...... ion of tumor suppressor genes.
@nl
type
label
Targeting activating mutations ...... sion of tumor suppressor genes
@ast
Targeting activating mutations ...... sion of tumor suppressor genes
@en
Targeting activating mutations ...... ion of tumor suppressor genes.
@nl
altLabel
Targeting activating mutations ...... sion of tumor suppressor genes
@en
prefLabel
Targeting activating mutations ...... sion of tumor suppressor genes
@ast
Targeting activating mutations ...... sion of tumor suppressor genes
@en
Targeting activating mutations ...... ion of tumor suppressor genes.
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Targeting activating mutations ...... sion of tumor suppressor genes
@en
P2093
Anja Heinemann
Dario Strbenac
Dilini Gunatilake
Gulietta M Pupo
Jessamy C Tiffen
Kavitha Gowrishankar
Ken Dutton-Regester
Nicholas K Hayward
Peter Hersey
P2860
P304
P3181
P356
10.18632/ONCOTARGET.4809
P407
P50
P577
2015-09-29T00:00:00Z